Aripiprazole for Patients with Schizophrenia and Schizoaffective Disorder: An Open-Label, Randomized, Study Versus Haloperidol (2009)
- Authors:
- USP affiliated authors: ELKIS, HELIO - FM ; GATTAZ, WAGNER FARID - FM
- Unidade: FM
- DOI: 10.1017/s1092852900000249
- Subjects: ESQUIZOFRENIA (TERAPIA); ESCALAS DE GRADUAÇÃO PSIQUIÁTRICA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: CNS Spectrums: International Journal of Neuropsychiatric Medicine
- ISSN: 1092-8529
- Volume/Número/Paginação/Ano: v. 14, n. 2, p. 93-102, February, 2009
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
OLIVEIRA, Irismar Reis de et al. Aripiprazole for Patients with Schizophrenia and Schizoaffective Disorder: An Open-Label, Randomized, Study Versus Haloperidol. CNS Spectrums: International Journal of Neuropsychiatric Medicine, v. 14, n. 2, p. 93-102, 2009Tradução . . Disponível em: https://doi.org/10.1017/s1092852900000249. Acesso em: 19 abr. 2024. -
APA
Oliveira, I. R. de, Elkis, H., Gattaz, W. F., Chaves, A. C., Sena, E. P. de, Souza, F. G. de M. e, et al. (2009). Aripiprazole for Patients with Schizophrenia and Schizoaffective Disorder: An Open-Label, Randomized, Study Versus Haloperidol. CNS Spectrums: International Journal of Neuropsychiatric Medicine, 14( 2), 93-102. doi:10.1017/s1092852900000249 -
NLM
Oliveira IR de, Elkis H, Gattaz WF, Chaves AC, Sena EP de, Souza FG de M e, Campos JA, Bueno JR, Silva JAC e, Louzã MR, Abreu PB de. Aripiprazole for Patients with Schizophrenia and Schizoaffective Disorder: An Open-Label, Randomized, Study Versus Haloperidol [Internet]. CNS Spectrums: International Journal of Neuropsychiatric Medicine. 2009 ; 14( 2): 93-102.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1017/s1092852900000249 -
Vancouver
Oliveira IR de, Elkis H, Gattaz WF, Chaves AC, Sena EP de, Souza FG de M e, Campos JA, Bueno JR, Silva JAC e, Louzã MR, Abreu PB de. Aripiprazole for Patients with Schizophrenia and Schizoaffective Disorder: An Open-Label, Randomized, Study Versus Haloperidol [Internet]. CNS Spectrums: International Journal of Neuropsychiatric Medicine. 2009 ; 14( 2): 93-102.[citado 2024 abr. 19 ] Available from: https://doi.org/10.1017/s1092852900000249 - Decreased S100-beta protein in schizophrenia: preliminary evidence
- Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study
- Treatment of patients with recently exacerbated schizophrenia with paliperidone palmitate: a pilot study of efficacy and tolerability
- A double blind placebo controlled study of conjugated estrogens added to haloperidol in patients with schizophrenia
- Leonhard´s classification of Schizophrenias and MRI brain abnormalities: preliminary results
- Niacin test in schizophrenia and in major depression
- Ventricular enlargement as a predictor of therapeutic response in schizophrenia: a structural MRI study
- Algumas recomendações para estudos com placebo
- Esquizofrenia e gênero
- Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia:: a double-blind study
Informações sobre o DOI: 10.1017/s1092852900000249 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
